Adjustment of Drug Dosage to Hemodialysis Patients

  • Frieder Keller
  • Ulrich Kunzendorf
  • Holger Hilt
  • Anke Schwarz
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 260)


Renal failure leads to reduced elimination and prolonged residence in the body of about one-half of all commonly used drugs. Kidney function should be taken into consideration for effective but nontoxic drug dosage. There is no simple parameter to describe kidney function. Glomerular filtration rate and drug elimination can only be sufficiently evaluated for clinical purposes by creatinine clearance (CCR). Drug elimination may be expressed as the rate constant (k) or elimination half-life (T1/2 = 1n2/k). The basic law of pharmacokinetics in renal insufficiency says that all drugs evidence a linear correlation between elimination rate constant (k) and creatinine clearance (Dettli 1977).
$${\rm k\ =\ knr\ +\ a\ CCR}$$


Hemodialysis Patient Therapeutic Drug Monitoring Plasma Protein Binding Trough Level Drug Elimination 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bailie, G. R., Mathews A., 1988, Quantitative and qualitative assessment of serum concentration monitoring and dosage adjustment of aminoglycosides, Therap. Drug Monitor, 10: 292–295.CrossRefGoogle Scholar
  2. Bakker-Woudenberg, I. A. J. M., Van den Berg, F. C., Vree, T. B., Baars, A. M., Michel, M. F., 1985, Relevance of serum protein binding of cefoxitin and cefazolin to their activities against Klebsiella pneumoniae pneumonia in rats, Antimicrob. Agents Chemother., 28: 654–659.PubMedGoogle Scholar
  3. Bennett, W. M., Aronoff, G. R., Morrison, G., Golper, T. A., Pulliam, J., Wolfson, M., Singer, I., 1983, Drug prescribing in renal failure: Dosing guidelines for adults, Am. J. Kidney Dis.. 3: 155–193.PubMedGoogle Scholar
  4. Blaser, J., Stone, B. B., Groner, M. C., Zinner, S. H., 1985, Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against pseudomas aeruginosa in an in vitro pharmacokinetic model, Antimicrob. Agents Chemother., 28: 64–68.PubMedGoogle Scholar
  5. Boettger, H. C., Oellerich, M., Sybrecht, G.W., 1988, Use of aminoglycosides in critically ill patients: individualization of dosage using bayesian statistics and pharmocokinetic principles, Therap. Drug Monitor, 10: 280–286.CrossRefGoogle Scholar
  6. Brater, D. C., Chennavasin, P., 1983, “Drug use in renal disease,”, Adis Press, Sidney, pp. 22–56.Google Scholar
  7. Chelluri, L., Jastremski, M. S., 1987, Inadequacy of standard aminoglycoside loading doses in acutely ill patients. Critical Care Medicine, 15: 1143–1145.PubMedCrossRefGoogle Scholar
  8. Dettli, L., 1977, Elimination kinetics and dosage adjustment of drugs in patients with kidney disease, Progr. Pharmacol., 1: 1–34.Google Scholar
  9. Franson, T. R., Quebbeman, E. J., Whipple, J., Thomson, R., Bubrick, J., Rosenberger, S. L., Ausman, R. K., 1988, Prospective comparison of traditional and pharmacokinetic aminoglycoside dosing methods, Critical Care Medicine, 16: 840–843.PubMedCrossRefGoogle Scholar
  10. Gerber, A. U., Brugger, H. P., Feller, C., Stritzko, T., Stadler, B., 1986, Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics, J. Infect. Disease, 153: 90–95.CrossRefGoogle Scholar
  11. Gibson, T. P., 1983, Principles of drug dose adjustment during hemodialysis, Am. J. Kidnev Pis., 3: 111–113.Google Scholar
  12. Ingerman, M. J., Pitsakis, P. G., Rosenberg, A. F., Levinson, M. E., 1986, The importance of pharmacodynamics in determining the dosing interval in therapy for experimental Pseudomonas endocarditis in the rat, J. Infect. Disease, 153: 707–801.CrossRefGoogle Scholar
  13. Kapusnik, J. E., Hackbarth, C. J., Chambers, H. F., Carpenter, T., Sande, M. A., 1988, Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J. Infect. Disease, 158: 7–12.CrossRefGoogle Scholar
  14. Keller, F., Hagner, K., Borner, K., Kemmerich, B., Lode, H., Offermann, G., Distler, A., 1986, Aminoglycoside dosage in hemodialysis patients, J. Clin. Pharmacol., 26: 690–695.PubMedGoogle Scholar
  15. Keller, F., Schwarz, A., 1987, “Pharmakokinetik bei Niereninsuffizienz”, Gustav Fischer, Stuttgart, pp. 164–193.Google Scholar
  16. Keller, F., Borner, K., Schwarz, A., Offermann, G., Lode, H., 1987, Therapeutic aminoglycoside monitoring in renal failure patients, Ther. Drug. Monitor, 9: 148–153.CrossRefGoogle Scholar
  17. Keller, F., Hilt, H., Haller, H., Walz, G., Kunzendorf, U., Offermann, G., 1988, Arzneimittelverluste bei Hämodialyse und spontaner Hämofiltration, in: Aspekte der Arzneitherapie bei Intensivpatienten, R. Dennhardt, G. Heinemeyer, H. J. Gramm, eds., Springer, Berlin, pp. 55–72.CrossRefGoogle Scholar
  18. Koenig, P., Guggenbichler, J. P., Semenitz, E., Foisner, W., 1986, Kill kinetics of bacteria under fluctuating concentrations of various antibiotics, Chemotherapy, 32: 44–58.CrossRefGoogle Scholar
  19. Kunzendorf, U., Keller, F., Walz, G., Haller, H., Offermann, G., Borner, K., Lode, H., 1988, Multivariate analysis of aminoglycoside levels in hemodialysis patients, Chemotherapy, 590. (in press)Google Scholar
  20. LeBel, M., Spino, M., 1988, Pulse dosing versus continuous infusion of antibiotics. Pharmacokinetic-pharmacodynamic considerations, Clin. Pharmacokinet., 14: 71–95.PubMedCrossRefGoogle Scholar
  21. Moore, R. D., Smith, C. R., Lietman, P. S., 1984, Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J. Infect. Dis., 149: 23–30.PubMedCrossRefGoogle Scholar
  22. Moore, R. D., Lietman, P. S., Smith, C. R., 1987, Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration, J. Infect. Pis., 155: 93–99.CrossRefGoogle Scholar
  23. Roosendaal, R., Bakker-Woudenberg, I. A. J. M., Van den Berg, J. C., Michel, M. F., 1985, Therapeutic efficacy of continuous intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats, J. Infect. Disease, 152: 373–377.CrossRefGoogle Scholar
  24. Rotheram, E. B., 1988, Clinical response and peak concentrations of aminoglycosides, J. Infect. Disease, 157: 395–396.CrossRefGoogle Scholar
  25. Wood, C. A., Norton, D. R., Kohlhepp, S. J., Kohnen, P. W., Porter, G. A., Houghton, D. C., Brummett, R. E., Bennett, W. M., Gilbert, D. N., 1988, The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess, J. Infect. Disease, 158: 13–22.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Frieder Keller
    • 1
  • Ulrich Kunzendorf
    • 1
  • Holger Hilt
    • 1
  • Anke Schwarz
    • 1
  1. 1.Klinikum Steglitz, Abteilung für Allgemeine Innere Medizin und Nephrologie, Abteilung für Anaesthesie und Operative IntensivmedizinFreie UniversitätBerlin 45West Germany

Personalised recommendations